Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.
An AI model can read tumor structure to predict which HER2-positive breast cancer patients will respond best to standard combination therapy, filling a critical gap in treatment planning.
This Signal Transduction & Targeted Therapy study presents an AI model that reads spatial tumor architecture to predict who will achieve pathologic complete response to neoadjuvant pertuzumab + trastuzumab in HER2-positive breast cancer. The interpretable spatial AI framework addresses a key clinical gap in HER2+ neoadjuvant treatment decision-making where no validated predictive biomarker currently exists.
What the study was
- Study design
- Retrospective validation study / AI model development and clinical cohort validation
- Population
- HER2-positive breast cancer patients receiving neoadjuvant chemotherapy with dual HER2 blockade
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Signal Transduction and Targeted Therapy
Why it surfaced
Signal Transduct Target Ther (IF ~40) publication combining spatial AI with a clinically important HER2+ neoadjuvant treatment selection problem. The interpretability aspect and the journal tier distinguish this from generic DL pathology papers. HER2+ breast cancer is a high-prevalence, well-resourced disease segment; a validated predictive AI tool here has near-term clinical implementation potential.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.